Results 111 to 120 of about 4,825 (166)

Overlapping Toxicities of Pembrolizumab and Lenvatinib: A Case of Capillary Leak Syndrome with Severe Erythroblastosis. [PDF]

Curr Oncol
Gkoufa A, Patsialos I, Stafylidis C, Anastasopoulou A, Adamou D, Gogas H, Diamantopoulos PT.   +6 more
europepmc   +1 more source

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach. [PDF]

Front Immunol
Nakhleh A, Mahamid A, Yechiel Y, Saiegh L, Zolotov S, Stemmer SM.   +5 more
europepmc   +1 more source

A Real-World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First-Line Lenvatinib. [PDF]

Cancer Med
Lee SW, Huang YJ, Tsai HJ, Lin YC, Chen CC, Lee TY, Chun-Peng Y.   +6 more
europepmc   +1 more source

Lenvatinib-Induced Acalculous Cholecystitis-An Often-Unrecognized Toxicity: A Case Series and Literature Review. [PDF]

Curr Oncol
Cortas C, Symeonidou C, Charalambous H.
europepmc   +1 more source

Comparative Analysis of Septin Modifiers, Forchlorfenuron and UR214-9, on Mitochondrial Fragmentation and Lytic Cell Death. [PDF]

Cytoskeleton (Hoboken)
Brokatzky D, Das R, Painter H, Singh RK, Mostowy S.   +4 more
europepmc   +1 more source

Long Term Disease Control of Brain Metastases From Chemotherapy-Resistant Endometrial Cancer With Lenvatinib and Pembrolizumab: A Case Report. [PDF]

J Obstet Gynaecol Res
Fujioka A, Takahashi A, Amano T, Tanaka Y, Yoneoka Y, Tsuji S.   +5 more
europepmc   +1 more source

DockingDB: An online reverse-docking database for plant hormone research. [PDF]

Plant Commun
Guo YX, Liu F, Xu XD, Xu G, Ye SY, Shao YH, Kong Y, Su Z, Zhao Q, Fu Q, Ma J, Song JM, Cai W, Ming Z, Chen LL.   +14 more
europepmc   +1 more source

Mild and efficient synthesis of carbamates using dioxazolones as bench-stable isocyanate surrogates: application in AChE-inhibiting agent development. [PDF]

RSC Adv
Wu Y, Liu X, Zuo F, Ding Y, Kang J, Wu J, Tang W, Zhang J.   +7 more
europepmc   +1 more source

Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report. [PDF]

BMC Womens Health
Liu S, Fu Y, Zuo K, Chen W, Chen X, Shan B, Yang H, Ye S.   +7 more
europepmc   +1 more source

Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer. [PDF]

PLoS One
Ahmad S, Qazi S, Bano N, Uddin R, Gautam PK, Raza K.   +5 more
europepmc   +1 more source